Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial
Journal of the International AIDS Society · 2023
DOI: 10.1002/jia2.26174 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the International AIDS Society, 2023. Verfasst von Linda Namutebi Barlow-Mosha und 33 weiteren Autor:innen. Beteiligte Einrichtung: Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda. Hauptthemen laut MEDLINE: Folic Acid, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Dolutegravir‐based antiretroviral therapy (ART) is the preferred antiretroviral treatment for children and adolescents living with HIV. A large surveillance study in Botswana previously raised concerns about an association between pre‐conception dolutegravir and neural tube defects. Before these concerns were subsequently resolved, we set up a sub‐study to look at the effect of dolutegravir on levels of folate and vitamin B12 in children and adolescents within the randomized ODYSSEY trial, as folate and vitamin B12 are known to play a crucial role in neural tube development.
Methods
We conducted the sub‐study among Ugandan ODYSSEY participants and compared folate and vitamin B12 between children randomized to dolutegravir‐based ART (DTG) and non‐dolutegravir‐based standard‐of‐care treatment (SOC). Plasma folate was measured at enrolment and week 4 on stored samples; in addition, plasma and red blood cell (RBC) folate and vitamin B12 were assayed at week ≥96 in prospectively collected samples. RBC mean corpuscular volume (MCV) was measured 24‐weekly in all ODYSSEY participants. Samples analysed in the sub‐study were collected between September 2016 and October 2020.
Results
A total of 229 children aged ≥6 years were included in the sub‐study with median age at trial enrolment of 12.3 (interquartile range [IQR] 9.0, 14.7) years, and CD4 count of 501 (IQR 228, 695); 112 (49%) children were male. Most participants (225/229, 98%) had plasma folate results at enrolment and 214 (93%) children had results available for RBC folate, vitamin B12 and plasma folate at week ≥96. MCV results were analysed on 679 children aged ≥6 years enrolled in ODYSSEY. At week 4, mean plasma folate was significantly higher in the dolutegravir arm than in SOC (difference [DTG‐SOC] 1.6 ng/ml, 95% CI 0.8, 2.3; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.
- Baylor College of Medicine Children's Foundation-Uganda, Kampala, Uganda.
- Joint Clinical Research Centre, Kampala, Uganda.
- Department of Pathology, ICON Central Laboratories Inc, Farmingdale, New York, USA.
- Infectious Diseases Institute Core Laboratory, Kampala, Uganda.
ORCID-Profile: Linda Namutebi Barlow-Mosha, Elizabeth Chappell, Anna Turkova
Förderung
- Medical Research Council
Zitieren
APA
Barlow-Mosha, L. N., Ahimbisibwe, G. M., Chappell, E., Amuge, P. M., Nanduudu, A., Kaudha, E., Amukele, T., Balamusani, D., Kafufu, B., Nimwesiga, A., Kataike, H., Namwanje, R., Kasangaki, G., Mulindwa, A., Muzorah, G. A., Bbuye, D., Musiime, V., Mujyambere, E., Ssenyonga, M., …, & ODYSSEY trial team (2023). Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26174
Vancouver
Barlow-Mosha LN, Ahimbisibwe GM, Chappell E, Amuge PM, Nanduudu A, Kaudha E, et al. Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial. Journal of the International AIDS Society. 2023. doi:10.1002/jia2.26174
BibTeX
@article{BarlowMosha2023,
author = {Barlow-Mosha, Linda Namutebi and Ahimbisibwe, Grace Miriam and Chappell, Elizabeth and Amuge, Pauline Mary and Nanduudu, Annet and Kaudha, Elizabeth and Amukele, Timothy and Balamusani, David and Kafufu, Bosco and Nimwesiga, Audrey and Kataike, Hajira and Namwanje, Rosemary and Kasangaki, Gladys and Mulindwa, Alice and Muzorah, Gerald Agaba and Bbuye, Dickson and Musiime, Victor and Mujyambere, Emmanuel and Ssenyonga, Mark and Mulima, Disan and Kyambadde, Raymonds Crespo and Namusanje, Josephine and Isabirye, Richard and Nabalamba, Mariam and Nakirya, Barbara Musoke and Kityo, Cissy and Kekitiinwa, Adeodata R and Giaquinto, Carlo and Copp, Andrew and Gibb, Diana M and Ford, Deborah and Musoke, Philippa and Turkova, Anna and ODYSSEY trial team, ODYSSEY trial team},
title = {Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial},
journal = {Journal of the International AIDS Society},
year = {2023},
doi = {10.1002/jia2.26174}
}
EUVIMED